Published in Medical Letter on the CDC and FDA, March 28th, 2004
The single-ascending-dose study involving approximately 46 subjects will be completed over a 6-week period by MDS Pharma Services in Phoenix, Arizona. Dosing was scheduled to commence on March 9th, 2004. This study will be used as the foundation to determine dosing of trans-ISA247 in future clinical trials for both psoriasis and renal transplantation.
"Based on analysis of previously collected data, trans-ISA247 is more bioavailable and therefore we expect to administer the drug at a lower dose...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.